Last reviewed · How we verify
The dexamethasone plus ropivacaine
At a glance
| Generic name | The dexamethasone plus ropivacaine |
|---|---|
| Sponsor | Beijing Tiantan Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Erector Spinae Plane Block for Acute Low Back Pain (NA)
- The Effect of Dexamethasone Administration Route in PENG Block for Pediatric Hip Surgery (PHASE4)
- Perineural vs Intravenous Dexamethasone as an Adjuvant to Brachial Plexus Block in Pediatric Hand Surgery (NA)
- PENG Block Variants With Dexamethasone and Dexmedetomidine in Older Adults (NA)
- Three Variants of the PENG Block With and Without Perineural Adjuvants in Older Adults (NA)
- Pericapsular Nerve Group Block Versus Intrathecal Morphine for Analgesia After Total Hip Arthroplasty (NA)
- Dexamethasone as ESPB Adjuvant in Lumbar Laminectomy (PHASE3)
- Comparison of Systemic Opioid (Morphine) and Pre-Incision Bilateral Scalp Nerve Block for Pain Management in Craniotomy Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- The dexamethasone plus ropivacaine CI brief — competitive landscape report
- The dexamethasone plus ropivacaine updates RSS · CI watch RSS
- Beijing Tiantan Hospital portfolio CI